<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157412</url>
  </required_header>
  <id_info>
    <org_study_id>Doxycycline in Nasal Polyps</org_study_id>
    <nct_id>NCT05157412</nct_id>
  </id_info>
  <brief_title>Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps</brief_title>
  <official_title>Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Doxycycline as an adjunct to systemic steroids in the treatment&#xD;
      of chronic rhinosinusitis with nasal polyps&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic rhinosinusitis with nasal polyps (CRSwNP) is a disease of the nose and paranasal&#xD;
      sinuses characterized by mucosal thickening and polyp formation. The prevalence of CRSwNP in&#xD;
      the general population ranges between 1 and 4%. It mostly affects adult individuals. The&#xD;
      treatment of CRSwNP can include the use of steroids, antibiotics, saline nasal spray,&#xD;
      mucolytics, topical/systemic decongestants, topical anticholinergics, anti-leukotrienes or&#xD;
      receptor blockers, and antihistamines. Steroids have a multitude of effects, including&#xD;
      inhibition of cytokine synthesis, reduction of the number of eosinophils and activated&#xD;
      eosinophils, anti-oedema effects and reduction of transudation. Topical corticosteroid&#xD;
      therapy is not effective in all patients, leading to the use of systemic glucocorticosteroids&#xD;
      and/or sinus surgery to control the disease. As a new approach, antibiotics are being used to&#xD;
      treat CRSwNP particularly in patients with disease exacerbated by the Staphylococcus aureus&#xD;
      enterotoxin. Antibiotics with anti- inflammatory effects can be used to treat patients with&#xD;
      chronic rhinosinusitis without polyps, which might be the precursor to CRSwNP. Long-term&#xD;
      treatment with these drugs, in selected cases, may be effective when corticosteroids fail.&#xD;
      Doxycycline has dual action: it has well described, broad-spectrum antibacterial activity&#xD;
      against S aureus as well as anti-inflammatory properties. It appears to be effective in&#xD;
      treatment of several chronic inflammatory airway diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polyp Size Score by Nasal Endoscopy</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>Every patient will undergo nasal endoscopy at the initial visit and every follow-up visit using a modified Lildholdt scoring system and given scores from 0 to 4. The total nasal polyp score is the sum of the scores from the right and left nostrils.&#xD;
0 = No polyps.&#xD;
= Small polyps in the middle meatus not reaching below the inferior border of the middle concha.&#xD;
= Polyps reaching below the lower boarder of the middle turbinate.&#xD;
= Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha.&#xD;
= Large polyps causing almost complete obstruction of the inferior meatus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological Evaluation</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>Multislice computed tomography scan of the nose and paranasal sinuses will be done before starting the treatment and at the end of the follow-up period (12 weeks) using the Lund-Mackay (LMK) scoring system where each sinus (maxillary, anterior ethmoidal, posterior ethmoidal, frontal, sphenoidal) is scored for opacification (0, no opacity; 1, partial opacity; 2, total opacity), and the osteo-meatal complex is scored 0 (no obstruction) or 2 (obstruction). The unilateral score goes from 0 to 12 whereas the bilateral score goes from 0 to 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>Complete Blood count specifically the eosinophilic count (both relative and absolute) will be documented at the initial visit and at the end of treatment. Values of each group will be compared to each other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatology</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>Using a questionnaire, all subjects will be asked to evaluate five symptoms (nasal obstruction, Rhinorrhea, postnasal discharge, hyposmia and facial pain) from 0 to 4.&#xD;
0 = no symptoms&#xD;
= mild symptoms&#xD;
= moderate symptoms&#xD;
= severe symptoms&#xD;
= very severe symptoms (intolerable) This will be assessed at the screening visit and follow-up visits at 3, 8 and 12 weeks as a sum of the five individual symptoms of a total score of 20.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nasal Polyps</condition>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Steroids + Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) along with Doxycycline (200 mg as a loading dose on the 1st day, followed by 100 mg once daily as a maintenance dose) for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroids Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100 mg Oral Tablet</intervention_name>
    <description>Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis</description>
    <arm_group_label>Steroids + Doxycycline</arm_group_label>
    <other_name>doxycycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone 20 mg</intervention_name>
    <description>Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other</description>
    <arm_group_label>Steroids + Doxycycline</arm_group_label>
    <arm_group_label>Steroids Only</arm_group_label>
    <other_name>prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1- Adult patients (aged 18 and over) with bilateral nasal polyps confirmed by nasal&#xD;
        endoscopy and CT scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CRS without nasal polyps.&#xD;
&#xD;
          2. Unilateral nasal polyps.&#xD;
&#xD;
          3. Pregnant and lactating women.&#xD;
&#xD;
          4. Patients younger than 18 years old.&#xD;
&#xD;
          5. Subjects with known allergic reaction to steroids or tetracyclines, hypertension,&#xD;
             diabetes (type 1 and 2), glaucoma, tuberculosis, herpes infection are excluded.&#xD;
&#xD;
          6. If any major complications to the drugs in use appeared in process.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai AbuElmagd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hamza El Shafie</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aly Ragaie</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mai AbuElmagd</last_name>
    <phone>+201112550253</phone>
    <email>May.20134387@med.au.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, Hens G, Hellings P, Ebbens FA, Fokkens W, Van Cauwenberge P, Bachert C. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010 May;125(5):1069-1076.e4. doi: 10.1016/j.jaci.2010.02.020.</citation>
    <PMID>20451040</PMID>
  </reference>
  <reference>
    <citation>Andrews AE, Bryson JM, Rowe-Jones JM. Site of origin of nasal polyps: relevance to pathogenesis and management. Rhinology. 2005 Sep;43(3):180-4.</citation>
    <PMID>16218510</PMID>
  </reference>
  <reference>
    <citation>Tetik F, Korkut AY, Kaya KS, Ucak I, Celebi I, Coskun BU. Comparison of the Oral Steroids, Macrolides and Combination Therapy in Nasal Polyposis Patients. Sisli Etfal Hastan Tip Bul. 2020 Jun 12;54(2):211-217. doi: 10.14744/SEMB.2018.40316. eCollection 2020.</citation>
    <PMID>32617061</PMID>
  </reference>
  <reference>
    <citation>Stammberger H. Rhinoscopic surgery. In: Settipane GA, Lund VJ, Bernstein JM, Tos M, editor. Nasal polyps: epidemiology, patho- genesis and treatment. Rhode Island: Ocean Side Pub; 1997. p.7-15.</citation>
  </reference>
  <reference>
    <citation>Hissaria P, Smith W, Wormald PJ, Taylor J, Vadas M, Gillis D, Kette F. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol. 2006 Jul;118(1):128-33. Epub 2006 May 19.</citation>
    <PMID>16815148</PMID>
  </reference>
  <reference>
    <citation>Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C, van Cauwenberge P, Bachert C. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004 Oct;114(4):981-3.</citation>
    <PMID>15480349</PMID>
  </reference>
  <reference>
    <citation>Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl. 1996;525:73-8.</citation>
    <PMID>8908275</PMID>
  </reference>
  <reference>
    <citation>Legent F, Bordure P, Beauvillain C, Berche P. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy. 1994;40 Suppl 1:8-15.</citation>
    <PMID>7805431</PMID>
  </reference>
  <reference>
    <citation>Subramanian HN, Schechtman KB, Hamilos DL. A retrospective analysis of treatment outcomes and time to relapse after intensive medical treatment for chronic sinusitis. Am J Rhinol. 2002 Nov-Dec;16(6):303-12.</citation>
    <PMID>12512904</PMID>
  </reference>
  <reference>
    <citation>Rempe S, Hayden JM, Robbins RA, Hoyt JC. Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):232-6. Review.</citation>
    <PMID>18220943</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>December 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mai Essam Ali AbuElmagd</investigator_full_name>
    <investigator_title>Residant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

